SRDX Valuation

Surmodics Inc

Add to Watchlist

Advanced Chart

38.000

+2.59(7.314%)1D

Overview
Forecast
Valuation
Earnings

SRDX Relative Valuation

SRDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SRDX is overvalued; if below, it's undervalued.

Historical Valuation

Surmodics Inc (SRDX) is now in the Fair zone, suggesting that its current forward PS ratio of 4.23 is considered Fairly compared with the five-year average of 330.11. The fair price of Surmodics Inc (SRDX) is between 27.19 to 47.29 according to relative valuation methord.

Relative Value

Fair Zone

27.19-47.29

Current Price：38.00

Fair

-112.79

Trailing

Forward

40.82

EV/EBITDA

Surmodics Inc. (SRDX) has a current EV/EBITDA of 40.82. The 5-year average EV/EBITDA is 23.06. The thresholds are as follows: Strongly Undervalued below -88.06, Undervalued between -88.06 and -32.50, Fairly Valued between 78.63 and -32.50, Overvalued between 78.63 and 134.19, and Strongly Overvalued above 134.19. The current Forward EV/EBITDA of 40.82 falls within the Historic Trend Line -Fairly Valued range.

-67.26

EV/EBIT

Surmodics Inc. (SRDX) has a current EV/EBIT of -67.26. The 5-year average EV/EBIT is -29.42. The thresholds are as follows: Strongly Undervalued below -357.63, Undervalued between -357.63 and -193.53, Fairly Valued between 134.68 and -193.53, Overvalued between 134.68 and 298.78, and Strongly Overvalued above 298.78. The current Forward EV/EBIT of -67.26 falls within the Historic Trend Line -Fairly Valued range.

4.23

Surmodics Inc. (SRDX) has a current PS of 4.23. The 5-year average PS is 4.60. The thresholds are as follows: Strongly Undervalued below 1.81, Undervalued between 1.81 and 3.20, Fairly Valued between 6.00 and 3.20, Overvalued between 6.00 and 7.40, and Strongly Overvalued above 7.40. The current Forward PS of 4.23 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Surmodics Inc. (SRDX) has a current P/OCF of 0.00. The 5-year average P/OCF is 30.07. The thresholds are as follows: Strongly Undervalued below -185.31, Undervalued between -185.31 and -77.62, Fairly Valued between 137.76 and -77.62, Overvalued between 137.76 and 245.45, and Strongly Overvalued above 245.45. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

394.30

P/FCF

Surmodics Inc. (SRDX) has a current P/FCF of 394.30. The 5-year average P/FCF is -508.09. The thresholds are as follows: Strongly Undervalued below -4280.85, Undervalued between -4280.85 and -2394.47, Fairly Valued between 1378.28 and -2394.47, Overvalued between 1378.28 and 3264.66, and Strongly Overvalued above 3264.66. The current Forward P/FCF of 394.30 falls within the Historic Trend Line -Fairly Valued range.

Surmodics Inc (SRDX) has a current Price-to-Book (P/B) ratio of 4.93. Compared to its 3-year average P/B ratio of 4.01 , the current P/B ratio is approximately 22.96% higher. Relative to its 5-year average P/B ratio of 4.30, the current P/B ratio is about 14.50% higher. Surmodics Inc (SRDX) has a Forward Free Cash Flow (FCF) yield of approximately -0.70%. Compared to its 3-year average FCF yield of -1.39%, the current FCF yield is approximately -49.70% lower. Relative to its 5-year average FCF yield of -0.43% , the current FCF yield is about 63.69% lower.

4.93

P/B

Median3y

4.01

Median5y

4.30

-0.70

FCF Yield

Median3y

-1.39

Median5y

-0.43

Competitors Valuation Multiple

The average P/S ratio for SRDX's competitors is 2.02, providing a benchmark for relative valuation. Surmodics Inc Corp (SRDX) exhibits a P/S ratio of 4.23, which is 109.74% above the industry average. Given its robust revenue growth of -2.55%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Cytek Biosciences Inc

Standard BioTools Inc

Performance Decomposition

Market capitalization of SRDX decreased by 4.11% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -24.51 to -30.92.

The secondary factor is the Revenue Growth, contributed -2.55%to the performance.

Overall, the performance of SRDX in the past 1 year is driven by P/E Change. Which is more unsustainable.

-2.55%

30.34M → 29.57M

Revenue Growth

-27.75%

-24.90 → -17.99

Margin Expansion

26.19%

-24.51 → -30.92

P/E Change

-4.11%